Respiratory syncytial virus vaccination in systemic autoimmune rheumatic diseases: a systematic review
Abstract
Respiratory syncytial virus (RSV) vaccination is available for older adults. Patients with systemic autoimmune rheumatic diseases (SARDs), including those receiving immunosuppressive therapies, were excluded from trials. Evidence to guide vaccination decisions is limited. We conducted a systematic review evaluating RSV epidemiology, vaccine effectiveness, immunogenicity and safety in adults with SARDs. Databases were searched from inception to 28 January 2026. Observational studies, clinical trials and pharmacovigilance reports were included. Evidence specific to disease-modifying antirheumatic drugs (DMARDs) was examined where available. Of the 249 unique records returned, 43 met the inclusion criteria. Six studies were identified in the supplementary search, yielding 49 studies in total. Only one study reported RSV outcomes in SARD patients. No study evaluated vaccine effectiveness stratified by DMARD class. Observational data suggest autoimmune and immunocompromising conditions are associated with increased RSV-associated hospitalization, although attribution is uncertain due to bias and data limitations. RSV vaccines demonstrated first-season effectiveness of 60–73% in immunocompromised adults, with evidence of attenuated and more rapidly waning protection compared with immunocompetent populations. Immunogenicity studies from RSV and other vaccine platforms indicate reduced seroconversion in immunosuppressed patients. No consistent autoimmune safety signals were identified, though data in SARD populations remain limited. RSV poses a relevant, though incompletely quantified, risk for SARD patients. Vaccination appears effective and safe in immunocompromised populations, but protection may wane more rapidly. The absence of DMARD-specific data represents an evidence gap. Until further evidence emerges, vaccination should be considered for eligible patients using a personalized framework.
Related
- Respiratory syncytial virus vaccination during pregnancy confers higher anti-RSV IgG concentration in neonatal cord than maternal blood
- Uptake of Respiratory Syncytial Virus Prefusion F Protein Vaccination during Pregnancy and nirsevimab among Infants over Two Seasons in a Single Health System.
- Maternal Vaccination vs Nirsevimab Use and Respiratory Syncytial Virus Infection Among Full-Term Infants
- Cardiac Complications of Infections Due to Respiratory Syncytial Virus and Human Metapneumovirus: A Systematic Review and Pooled Analysis of Clinical Features.
- Towards a Novel Diagnostic Tool for Autoimmune Rheumatic Diseases: Classification of SLE Using FTIR Spectroscopy and Machine Learning
BibTeX
@article{allen2026respiratory,
title = {{Respiratory syncytial virus vaccination in systemic autoimmune rheumatic diseases: a systematic review}},
author = {Victoria Allen and Maryam Adas and Liyang Pan and Nilay Joshi and Mark Russell and Katie Bechman and James Galloway},
journal = {Rheumatology (Oxford, England)},
year = {2026},
month = sep,
doi = {10.1093/rheumatology/keag513},
url = {https://doi.org/10.1093/rheumatology/keag513},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Respiratory syncytial virus vaccination in systemic autoimmune rheumatic diseases: a systematic review
AU - Victoria Allen
AU - Maryam Adas
AU - Liyang Pan
AU - Nilay Joshi
AU - Mark Russell
AU - Katie Bechman
AU - James Galloway
PY - 2026
DA - 2026/09/17
JO - Rheumatology (Oxford, England)
DO - 10.1093/rheumatology/keag513
UR - https://doi.org/10.1093/rheumatology/keag513
AB - Respiratory syncytial virus (RSV) vaccination is available for older adults. Patients with systemic autoimmune rheumatic diseases (SARDs), including those receiving immunosuppressive therapies, were excluded from trials. Evidence to guide vaccination decisions is limited. We conducted a systematic review evaluating RSV epidemiology, vaccine effectiveness, immunogenicity and safety in adults with SARDs. Databases were searched from inception to 28 January 2026. Observational studies, clinical trials and pharmacovigilance reports were included. Evidence specific to disease-modifying antirheumatic drugs (DMARDs) was examined where available. Of the 249 unique records returned, 43 met the inclusion criteria. Six studies were identified in the supplementary search, yielding 49 studies in total. Only one study reported RSV outcomes in SARD patients. No study evaluated vaccine effectiveness stratified by DMARD class. Observational data suggest autoimmune and immunocompromising conditions are associated with increased RSV-associated hospitalization, although attribution is uncertain due to bias and data limitations. RSV vaccines demonstrated first-season effectiveness of 60–73% in immunocompromised adults, with evidence of attenuated and more rapidly waning protection compared with immunocompetent populations. Immunogenicity studies from RSV and other vaccine platforms indicate reduced seroconversion in immunosuppressed patients. No consistent autoimmune safety signals were identified, though data in SARD populations remain limited. RSV poses a relevant, though incompletely quantified, risk for SARD patients. Vaccination appears effective and safe in immunocompromised populations, but protection may wane more rapidly. The absence of DMARD-specific data represents an evidence gap. Until further evidence emerges, vaccination should be considered for eligible patients using a personalized framework.
SN - 1462-0324
SN - 1462-0332
ER -